OBJECTIVE: To explore whether or not statins have any impact on the progression of components of benign prostatic hyperplasia (lower urinary tract symptoms severity, prostate volume and serum prostate specific antigen (PSA) when combined with other agents inhibiting growth of prostate cells. MATERIALS AND METHODS: This was a preliminary, clinical study. Eligible patients were aged > 50 yrs, with International Prostate Symptom Score (IPSS) between 9 and 19, total prostate volume (TPV) >40 mL, and serum PSA > 1.5 ng/mL. Patients were divided in two groups: those with and those without lipidemia. After selection, eligible BPH patients with lipidemia (n = 18) were prescribed lovastatin 80 mg daily and finasteride 5 mg daily, while eligible patients without lipidemia (n = 15) were prescribed only finasteride 5 mg daily. IPSS, TPV and serum PSA were evaluated at end point (4 months). RESULTS: There was no difference between the two groups on the primary end point of mean change from baseline in IPSS (p = 0.69), TPV (p = 0.90) and PSA (p = 0.16) after 4 months of treatment. CONCLUSIONS: Short-term lovastatin treatment does not seem to have any effect on IPSS, TPV and PSA in men with prostatic enlargement due to presumed BPH.
OBJECTIVE: To explore whether or not statins have any impact on the progression of components of benign prostatic hyperplasia (lower urinary tract symptoms severity, prostate volume and serum prostate specific antigen (PSA) when combined with other agents inhibiting growth of prostate cells. MATERIALS AND METHODS: This was a preliminary, clinical study. Eligible patients were aged > 50 yrs, with International Prostate Symptom Score (IPSS) between 9 and 19, total prostate volume (TPV) >40 mL, and serum PSA > 1.5 ng/mL. Patients were divided in two groups: those with and those without lipidemia. After selection, eligible BPH patients with lipidemia (n = 18) were prescribed lovastatin 80 mg daily and finasteride 5 mg daily, while eligible patients without lipidemia (n = 15) were prescribed only finasteride 5 mg daily. IPSS, TPV and serum PSA were evaluated at end point (4 months). RESULTS: There was no difference between the two groups on the primary end point of mean change from baseline in IPSS (p = 0.69), TPV (p = 0.90) and PSA (p = 0.16) after 4 months of treatment. CONCLUSIONS: Short-term lovastatin treatment does not seem to have any effect on IPSS, TPV and PSA in men with prostatic enlargement due to presumed BPH.
Authors: Susan A Hall; Gretchen R Chiu; Carol L Link; William D Steers; Varant Kupelian; John B McKinlay Journal: Ann Epidemiol Date: 2011-03 Impact factor: 3.797
Authors: Emma H Allott; Ilona Csizmadi; Lauren E Howard; Roberto L Muller; Daniel M Moreira; Gerald L Andriole; Claus G Roehrborn; Stephen J Freedland Journal: BJU Int Date: 2019-09-27 Impact factor: 5.588
Authors: Jennifer L St Sauver; Steven J Jacobsen; Debra J Jacobson; Michaela E McGree; Cynthia J Girman; Ajay Nehra; Veronique L Roger; Michael M Lieber Journal: BJU Int Date: 2010-08-26 Impact factor: 5.588
Authors: Hanan Goldberg; Faizan K Mohsin; Thenappan Chandrasekar; Christopher J D Wallis; Zachary Klaassen; Ardalan E Ahmad; Refik Saskin; Miran Kenk; Olli Saarela; Girish S Kulkarni; Shabbir M H Alibhai; Neil Fleshner Journal: Can Urol Assoc J Date: 2022-05 Impact factor: 2.052